Immunovia
0.16 SEK
-0.25 %
Less than 1K followers
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Immunovia
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.4 | 0.4 | 0.8 | 1.2 | 1.6 | 0.9 | 0.7 |
| growth-% | 1.7 % | 133.1 % | 36.3 % | 37.4 % | -41.1 % | -26.3 % | |
| EBITDA | -105.8 | -84.6 | -147.6 | -166.2 | -154.7 | -96.0 | -78.1 |
| EBIT | -114.2 | -134.3 | -166.6 | -191.2 | -296.5 | -109.4 | -80.4 |
| Profit before taxes | -114.5 | -146.0 | -156.0 | -168.1 | -309.4 | -76.5 | -145.9 |
| Net income | -114.5 | -146.0 | -156.0 | -168.1 | -309.4 | -76.5 | -145.9 |
| EPS | -2.10 | -2.45 | -2.47 | -2.66 | -3.07 | -0.72 | -0.42 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -29,719.7 % | -23,359.1 % | -17,484.0 % | -14,455.7 % | -9,793.7 % | -10,321.5 % | -11,395.6 % |
| EBIT-% | -32,092.1 % | -37,111.3 % | -19,742.7 % | -16,621.7 % | -18,763.3 % | -11,764.5 % | -11,735.0 % |
| ROE | -32.0 % | -24.4 % | -35.9 % | -68.9 % | -461.9 % | -657.0 % | -225.4 % |
| ROI | -27.3 % | -22.1 % | -31.6 % | -55.9 % | -313.6 % | -231.7 % | -165.4 % |